BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 32431227)

  • 1. COVID-19 and hypertension.
    Kulkarni S; Jenner BL; Wilkinson I
    J Renin Angiotensin Aldosterone Syst; 2020; 21(2):1470320320927851. PubMed ID: 32431227
    [No Abstract]   [Full Text] [Related]  

  • 2. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19.
    Vaduganathan M; Vardeny O; Michel T; McMurray JJV; Pfeffer MA; Solomon SD
    N Engl J Med; 2020 Apr; 382(17):1653-1659. PubMed ID: 32227760
    [No Abstract]   [Full Text] [Related]  

  • 3. Coronavirus Disease 2019 (COVID-19): Do Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect?
    Sommerstein R; Kochen MM; Messerli FH; Gräni C
    J Am Heart Assoc; 2020 Apr; 9(7):e016509. PubMed ID: 32233753
    [No Abstract]   [Full Text] [Related]  

  • 4. COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence?
    Patel AB; Verma A
    JAMA; 2020 May; 323(18):1769-1770. PubMed ID: 32208485
    [No Abstract]   [Full Text] [Related]  

  • 5. Drugs and the renin-angiotensin system in covid-19.
    Aronson JK; Ferner RE
    BMJ; 2020 Apr; 369():m1313. PubMed ID: 32241880
    [No Abstract]   [Full Text] [Related]  

  • 6. The interplay of hypertension, ACE-2 and SARS-CoV-2: Emerging data as the "Ariadne's thread" for the "labyrinth" of COVID-19.
    Tsioufis C; Dimitriadis K; Tousoulis D
    Hellenic J Cardiol; 2020; 61(1):31-33. PubMed ID: 32450334
    [No Abstract]   [Full Text] [Related]  

  • 7. Potential differential effects of renin-angiotensin system inhibitors on SARS-CoV-2 infection and lung injury in COVID-19.
    Furuhashi M; Moniwa N; Takizawa H; Ura N; Shimamoto K
    Hypertens Res; 2020 Aug; 43(8):837-840. PubMed ID: 32433641
    [No Abstract]   [Full Text] [Related]  

  • 8. The role of ACEIs/ARBs in COVID-19: Friend or foe?
    Zhou Z; Qiu Y; Tao J
    Med Hypotheses; 2020 Sep; 142():109810. PubMed ID: 32413701
    [No Abstract]   [Full Text] [Related]  

  • 9. SARS-CoV-2 downregulation of ACE2 and pleiotropic effects of ACEIs/ARBs.
    Ciulla MM
    Hypertens Res; 2020 Sep; 43(9):985-986. PubMed ID: 32523133
    [No Abstract]   [Full Text] [Related]  

  • 10. Would ACEIs/ARBs be beneficial for COVID-19 patients without hypertension?
    Huang Y; Xie C; Chen X; Hong Q; Huang H
    Pharmacol Res; 2020 Sep; 159():104959. PubMed ID: 32505834
    [No Abstract]   [Full Text] [Related]  

  • 11. COVID-19 and the cardiovascular system.
    Zheng YY; Ma YT; Zhang JY; Xie X
    Nat Rev Cardiol; 2020 May; 17(5):259-260. PubMed ID: 32139904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?
    Esler M; Esler D
    J Hypertens; 2020 May; 38(5):781-782. PubMed ID: 32195824
    [No Abstract]   [Full Text] [Related]  

  • 13. A consensus statement on the use of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in relation to COVID-19 (corona virus disease 2019).
    Talreja H; Tan J; Dawes M; Supershad S; Rabindranath K; Fisher J; Valappil S; van der Merwe V; Wong L; van der Merwe W; Paton J
    N Z Med J; 2020 Apr; 133(1512):85-87. PubMed ID: 32242182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Facts and reflections on COVID-19 and anti-hypertensives drugs.
    Marin GH
    Drug Discov Ther; 2020 May; 14(2):105-106. PubMed ID: 32213760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19 and cardiovascular disease: What we know, what we think we know, and what we need to know.
    Dhawan R; Gundry RL; Brett-Major DM; Mahr C; Thiele GM; Lindsey ML; Anderson DR
    J Mol Cell Cardiol; 2020 Jul; 144():12-14. PubMed ID: 32339565
    [No Abstract]   [Full Text] [Related]  

  • 16. Central involvement of SARS-CoV-2 may aggravate ARDS and hypertension.
    Cure E; Cumhur Cure M; Vatansev H
    J Renin Angiotensin Aldosterone Syst; 2020; 21(4):1470320320972015. PubMed ID: 33169637
    [No Abstract]   [Full Text] [Related]  

  • 17. ACE2 (Angiotensin-Converting Enzyme 2), COVID-19, and ACE Inhibitor and Ang II (Angiotensin II) Receptor Blocker Use During the Pandemic: The Pediatric Perspective.
    South AM; Brady TM; Flynn JT
    Hypertension; 2020 Jul; 76(1):16-22. PubMed ID: 32367746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular disease, heart failure and COVID-19.
    Faconti L; Chowienczyk PJ; Shah AM
    J Renin Angiotensin Aldosterone Syst; 2020; 21(2):1470320320926903. PubMed ID: 32434431
    [No Abstract]   [Full Text] [Related]  

  • 19. COVID-19 and the pulmonary vascular injury.
    Dai HL; Guang XF
    J Renin Angiotensin Aldosterone Syst; 2020; 21(4):1470320320972276. PubMed ID: 33176538
    [No Abstract]   [Full Text] [Related]  

  • 20. Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS).
    Cadegiani FA; Goren A; Wambier CG
    Med Hypotheses; 2020 Oct; 143():110112. PubMed ID: 32721806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.